Ultragenyx Announces Initiation Of Dosing In Second Cohort Of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy For The Treatment Of Wilson Disease
Portfolio Pulse from Happy Mohamed
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has initiated dosing in the second cohort of its Phase 1/2/3 Cyprus2+ trial for UX701 gene therapy, aimed at treating Wilson disease. The first dose cohort was well tolerated with no unexpected adverse events. The company is on track to complete enrollment in Stage 1 of the trial this year and expects to share initial data in the first half of 2024.
July 31, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ultragenyx's initiation of dosing in the second cohort of its Phase 1/2/3 trial for UX701 gene therapy could potentially impact its stock positively if the trial continues to show positive results.
The news of Ultragenyx's progress in its Phase 1/2/3 trial for UX701 gene therapy is directly related to the company's core business. If the trial continues to show positive results, it could potentially lead to a new product offering, which could boost the company's revenues and positively impact its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100